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The management of patients with lung cancer has undergone
significant improvement in the last decade in the United Kingdom.
The 5-year survival for all patients diagnosed with lung cancer had
remained unchanged at 5% over the previous decade, well behind
Europe and the United States. Together, government and medical
bodies produced guidelines based on best available evidence. The
dissemination of these guidelines into clinical practice became the
remit of Cancer Networks. The establishment of Multidisciplinary
teams (MDTs) has streamlined care and allowed individual teams to
discuss patients’managementwithin awider body of expertise. The
CancerNetworkquality assurance teamassesses theMDTs to ensure
that standards are maintained. Though the efficacy of the MDTs in
improving quality and consistency of care for patients with lung
cancer is irrefutable, the effects on overall survival rates are less
certain. Themajority of patients have advanced incurable disease at
presentation. Changes in awareness of the general public and in the
primary care setting are required to address this issue. Severe co-
morbidities in patients with potentially curable disease can also
preclude operative treatment. The delivery of specialized care for
patients with lung cancer has improved dramatically in the United
Kingdomwith the advent of national guidelines and the local MDT.
These measures may not be enough in remedying the poor long-
term survival of patients with lung cancer in the United Kingdom
without attention to underlying cause. A holistic attitude to the ‘‘Big
Three’’ smoking-induced diseases offers hope of novel approach to
this problem.
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Lung Cancer kills over 30,000 people each year in the United
Kingdom, accounting for 5.6% of all UK deaths (1). This is
greater than deaths from the next three most common malignan-
cies combined (breast, colorectal, and prostate cancers). Survival
rates for lung cancer in the United Kingdom are very poor and
have not improved in the last 30 years (Figure 1). For patients
diagnosed between 1993 and 1995 and followed up to 2000, only
5.5% are alive after 5 years. This compares with 13% 5-year
survival reported in the United States and similar proportions for
several other European Community countries (Figure 2) (2, 3).
Surgical resection rates, a marker of outcome, are lower in the
United Kingdom (11%) compared with the rest of Europe (17%)
and North America (21%), and vary by threefold between health
authorities in England (4, 5). The availability of care to all in the
United Kingdom as compared with other insurance-based sys-
tems may result in differences in the number of reported patients
with lung cancer. However, there is still variation in lung cancer
survival between regions of the United Kingdom—for example,
5-year relative survival rates varied fourfold (2.2–8.8%) for
patients diagnosed in England in 199321995 (6).
The ‘‘cancer lottery’’—that is, where patients’ chances
of receiving optimum management depended on their refer-
ral—was exemplified by historical registry data. Variations in
patterns of care meant that over 40% of patients with lung
cancer were managed by physicians involved in the care of less
than 10 patients with lung cancer a year; a significant number
were general surgeons or elderly care physicians. The confir-
mation of histology and use of active treatment were sub-
stantially less in this group (7).
Such comparisons highlighted the need to improve the
standards of care for UK patients with lung cancer. Three
thousand lives a year could be saved by improving UK 5-year
survival rates to match the best. In fact, a doubling in survival
figures could be achieved purely by the uniform application of
current best UK management strategies. The following de-
scription exemplifies the approach by government and medical
bodies to such a grave health inequality. This approach may
have wider applicability.
THE GOVERNMENT AND MEDICAL
PROFESSION RESPOND
NICE (National Institute of Clinical Excellence) is an inde-
pendent NHS organization responsible for providing national
guidance on treatments and care for those using the NHS in
England and Wales. NICE guidance and recommendations are
prepared by independent groups that include professionals
working in the NHS and involved external individuals.
NICE in parallel with their Scottish counterpart SIGN (Scottish
Intercollegiate Guidelines Network) produced lung cancer guide-
lines based on best available evidence in 2001 updated in 2005 (4, 8).
Guidelines on the selection of patients with lung cancer for
surgery was established by a joint BTS/SCTS Working Party
comprising a core Writing Group taking advice from specialist
advisors representing the Royal College of Radiologists and
the Royal College of Pathologists (9). The major areas for
concern in terms of fitness for surgery were considered to be
age, pulmonary function, cardiovascular fitness, nutrition, and
performance status, and in terms of operability to be diagnosis
and staging, adjuvant therapy, the operations available, locally
advanced disease, and small cell lung cancer.
These clinical guidelines sit alongside, but do not replace, the
knowledge and skills of experienced health professionals. The
dissemination of these guidelines into clinical practice became
the remit of cancer networks.
THE CANCER NETWORK: DELIVERY OF CARE
Currently, there are around 30 cancer networks across the
country whose populations range from 600,000 to three million.
The cancer networks were established after the recommenda-
tions of the Calman-Hine report (1995) and NHS Cancer Plan
(2000) (10, 11). Cancer networks are the vehicle for ensuring
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that all patients within their population area have equal access
to the highest quality of cancer services available.
For example the Pan Birmingham Cancer Network (one of
the networks in which the authors practice) has four core
objectives (http://www.birminghamcancer.nhs.uk):
1. Develop multidisciplinary teams (MDTs) and make
arrangements to ensure that all patients are reviewed by
them before treatment.
2. Agree common protocols and service patterns to tackle
variations and make best use of resources available.
3. Develop all aspects of local cancer services: prevention,
screening, diagnosis, treatment, supportive and specialist
palliative care.
4. Develop workforce education, training, and facility strat-
egies.
The Cancer Network links with the Cancer Services Im-
provement Partnership, which is part of the National Modern-
isation Agency.
NETWORK AUDIT: QUALITY ASSURANCE
Network audit reviews all aspects of patient care to inform
practice, service improvement, policy, and investment. Local
review of cancer services is undertaken by Network Site–Specific
Groups, in part by using Key Performance Indicators (KPIs).
KPIs help monitor improvements in cancer treatment and
consistency and provide reassurance and evidence that cancer
services are safe, equitable, and deliver good outcomes for
patients. Network Site–Specific Groups have agreed KPIs with
reference to the measures described within the NICE Improving
Outcomes Guidance and the Healthcare Commission–sponsored
national cancer audits. Monitoring cancer waiting times as set out
the Cancer Plan are one such KPI (12). Patients should be treated
within 31 days of the decision to treat and within 62 days of their
urgent referral. These targets are based on potential effects of
delays in diagnosis or treatment on survival and quality of life and
estimated time for doubling size of cancer.
The National Clinical Audit Support Program (NCASP),
commissioned by the health care commission, manages the
national clinical audits for cancer, coronary heart disease, and
diabetes. The National Cancer Dataset is the approved standard
for the collection of cancer data and provides a tool for cancer
service providers to share data across healthcare boundaries, to
enable comparison of cancer information, to monitor outcomes,
and to improve patient care. The dataset has both generic and
site-specific data items. Lung cancer was one of four types of
cancer to be included in the first wave of this initiative, named
the LUCADA (LUng CAncer DAta) project. After pilot data
collection in 2004, the Healthcare Commission (HCC) agreed to
fund the project and the schemes have been rolled out to the
rest of the country.
LUCADA will collect data on ‘‘the incidence, nature, geo-
graphical distribution and treatment of lung cancer’’ with the
‘‘ultimate aim of improving patient care and outcomes’’ (13).
Figure 1. Relative survival for lung cancer, England and
Wales, 1971–2001. In England and Wales, 25% of all
patients with lung cancer are alive 1 year after diagnosis,
falling to 7% at 5 years. The 5-year survival has not
significantly improved over the last two decades. (Reprin-
ted by permission from Reference 28.)
Figure 2. Age-standardized (European) mortality rates, lung cancer,
EU countries, 2002. Lung cancer incidence rates vary hugely between
different regions of the world. The highest rates of lung cancer in men
are found in central and eastern Europe. (Reprinted by permission from
Reference 29.)
Naidu and Rajesh: Management of Lung Cancer in the United Kingdom 817
MDTs
MDTs may include general physicians and nurses, chest physi-
cians, palliative care physicians, clinical and medical oncolo-
gists, thoracic surgeons, geriatricians, cellular pathologists,
radiologists, radiographers, occupational therapists, specialist
nurses, physiotherapists, dieticians, pharmacists, and clinical
psychologists.
Input from many different professionals is required in the
management of patients with lung cancer, and so the MDTs
are especially appropriate in reducing delays caused by cross-
referral between specialists.
The importance of MDTs has been noted by a number of
previous reports: the Calman-Hine report, Improving Outcomes
in Lung Cancer (NHS Executive) (14), NHS Cancer Plan,
Clinical Oncology Information Network guidelines (15), British
Thoracic Society recommendations on organizing care for lung
cancer patients (16), and the American College of Chest
Physicians (17).
‘‘All patients with a likely diagnosis of lung cancer should
be referred to a member of a lung cancer multi-disciplinary
team (usually a chest physician). The care of all patients with
a working diagnosis of lung cancer should be discussed at a lung
cancer multi-disciplinary team meeting’’ (8). It is important that
there is adequate administrative support for MDTs.
Studies of multidisciplinary breast cancer ‘‘one-stop shop-
ping’’ clinics have shown an increase in patient satisfaction
and a shorter time from diagnosis to treatment (42.2 days versus
29.6 days) (18).
There is some evidence that such a specialist respiratory
service leads to a more expeditious and appropriate care and
that a fast-track system of diagnosis and staging can increase the
proportion of patients reaching surgery (19, 20).
From the 2007 LUCADA report, 86% of patients with lung
cancer were discussed at an MDT; 67% had their lung cancer
histologically confirmed, and 48% received some form of active
anticancer treatment. These represent improvements compared
with historical data (13). A dedicated specialist thoracic surgeon
providing a service within the MDT may almost double the
resection rate for potentially curable lung cancer (21, 22).
Few studies have looked at improvement in survival rates, and
those that have are difficult to interpret because of historical or
selected controls (23, 24).
Nevertheless, a multidisciplinary team approach to the man-
agement of the patient with suspected or known lung cancer has
improved the quality of care.
THE FUTURE
Despite these advances in management, the survival in patients
with lung cancer in the United Kingdom is lower than in other
similar European countries. Though guidelines and cancer
networks may help deal with inequality of health care, this
may not necessarily improve survival from lung cancer because
of specific biology. Patients with lung cancer in the United
Kingdom present at a later stage and with more aggressive types
of tumor—namely, large and small cell carcinoma. They have
higher co-morbidity than patients in comparable European
cities (25). Causes for this worse health include a higher rate
of smokers and of occupational risk, delayed diagnosis, socio-
economic status, and more advanced stage of disease at pre-
sentation (25, 26). As a result, the resection rate is still
significantly lower and survival worse.
Delayed presentation means that the majority of patients
have advanced incurable disease at the outset. Wider changes of
awareness in the general public and in the primary care setting
are required to address this issue. Severe co-morbidities in
patients with potentially curable disease can also preclude
operative treatment. Novel approaches to curative treatment
in these patients should be considered.
An approach to addressing the root cause of poor outcome
is exemplified by the UK Lung Cancer Consortium (UKLCC).
This partnership of leading lung cancer experts, senior NHS and
Department of Health professionals, charities, and healthcare
companies formed with the aim ‘‘To double one-year lung
cancer survival by 2010 and five-year survival by 2015’’ (27).
Their objectives include raising the general public’s awareness
of lung cancer, encouraging earlier presentation and symptom
recognition, but also raising political awareness of lung cancer.
A 12-point plan outlines an aggressive strategy for prevention,
screening, awareness, information and support, diagnosis and
staging, treatment, end of life care, MDT management, work-
force capacity, research, and data collection.
Nine out of 10 lung cancers are associated with smoking. A
holistic attitude to the ‘‘Big Three’’ major smoking-induced
diseases—cardiovascular disease, COPD, and lung cancer—
represents a novel approach which focuses on common path-
ways. Attention is centered on ‘‘screening for susceptibility.’’ In
susceptible individuals, CT screening for early diagnosis might
improve the outcome. Novel and innovative treatments for smokers
and ex-smokers will take into account the co-morbidities of this
group. This change in approach to smoking-induced diseases
would eventually be reflected in government- and medical body–
issued guidelines.
CONCLUSIONS
The care of lung cancer patients in the United Kingdom has
undergone significant improvement in the last decade in re-
sponse to health inequalities between regions and the poor
overall 5-year survival compared with Europe and the United
States. This example shows how a centralized state-run health
care system can respond to improve standards.
The department of health in conjunction with the Royal
Colleges set about addressing this issue. NICE (National In-
stitute of Clinical Excellence) in parallel with SIGN (Scottish
Intercollegiate Guidelines Network) produced guidelines based
on best available evidence. The British Thoracic Society set up
a working party to produce guidelines regarding surgical ope-
rability and respectability. Cancer Networks were made re-
sponsible for ensuring equal access to the highest quality of
cancer services by the use of these guidelines. Its most signif-
icant achievement has been the establishment of MDTs. Patient
management plans are expedited by the MDT, thus delivering
rapid, consistent, good-quality clinical care. Quality assurance is
robustly established in this process. However, an overall im-
provement in survival rates from lung cancer is not apparent
because of advanced presentation of disease and severe smoking-
related co-morbidities. Broader approaches to management are
paramount if survival rates of lung cancer are to improve.
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